Research Analysis · Everyday foundations
Look AHEAD improved weight and risk factors—not cardiovascular event rates
In 5,145 adults with type 2 diabetes and overweight or obesity, intensive lifestyle intervention produced greater sustained weight loss and improved several risk factors. It did not significantly reduce the trial’s primary cardiovascular outcome.
By Lois Rune
Published August 26, 2026 · Updated August 26, 2026 · AI-assistance disclosure
Evidence scope
Human cardiovascular events and function · large randomized trial
Meaningful weight loss, no cardiovascular-event reduction
The program changed weight, fitness and several risk factors. The primary event count—403 versus 418—did not show a statistically significant cardiovascular benefit, and the trial stopped early for futility on that outcome.
What Look AHEAD tested
Look AHEAD randomized 5,145 adults age 45 to 75 with type 2 diabetes and overweight or obesity to an intensive lifestyle program or diabetes support and education. The intervention emphasized calorie reduction and physical activity with frequent counseling.
What changed—and what did not
At one year, mean weight loss was 8.6% with intensive lifestyle and 0.7% in the comparison group. At the end of follow-up, the corresponding losses were 6.0% and 3.5%. The primary cardiovascular outcome occurred in 403 versus 418 participants, a hazard ratio of 0.95 with P=0.51.
Limits, correction and harms
The trial stopped for futility on its primary cardiovascular outcome, so it cannot rule out smaller effects. A published correction added hospitalization for angina to one secondary composite in Table 2; it did not change the primary result. Self-reported fractures differed, while adjudicated fracture results did not.
Funding and conflicts
Look AHEAD was supported by NIH and HHS agencies plus listed corporate contributions. The paper states corporate supporters had no role in design, analysis or reporting; author disclosures are linked with the article.
Sources and editorial method
Evidence review was completed separately from prose drafting across three documented passes. Primary identifiers, trial status, corrections, funding, conflicts, limitations and later context were checked before publication. See the governed issue record.
More metabolic-health trial outcomes
A diabetes-prevention trial separating incidence from later complications
DPP prevention effects persisted for 15 years—without an overall microvascular difference
Among adults at high risk for type 2 diabetes, the DPP lifestyle and metformin groups still had lower cumulative diabetes incidence after 15 years. The randomized groups did not differ significantly in the study’s aggregate microvascular outcome.
Evidence scopeHuman diabetes incidence and microvascular outcomes · long randomized follow-up
A high-risk diabetes trial centered on cardiovascular outcomes and safety
ACCORD’s intensive glucose target increased mortality and was stopped early
In 10,251 adults with type 2 diabetes and high cardiovascular risk, an intensive multi-drug strategy targeting near-normal glycated hemoglobin did not significantly reduce the primary cardiovascular outcome and increased all-cause mortality.
Evidence scopeHuman cardiovascular events, mortality and safety · large randomized trial
Publication history
Published August 26, 2026 after three research passes, claim-level evidence review, editorial review and deterministic source checks. No correction or retraction affecting the central result was identified at publication.